


Provided for non-commercial research and education use.
Not for reproduction, distribution or commercial use.



This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution and sharing with colleagues.

Other uses, including reproduction and distribution, or selling or licensing copies, or posting to personal, institutional or third party websites are prohibited.

In most cases authors are permitted to post their version of the article (e.g. in Word or Tex form) to their personal website or institutional repository. Authors requiring further information regarding Elsevier's archiving and manuscript policies are encouraged to visit:

<http://www.elsevier.com/copyright>

Contents lists available at [SciVerse ScienceDirect](http://www.sciencedirect.com)

Gene

journal homepage: www.elsevier.com/locate/gene

Gender-specific methylation differences in relation to prenatal exposure to cigarette smoke

Susan K. Murphy ^{a,*}, Abayomi Adigun ^a, Zhiqing Huang ^a, Francine Overcash ^b, Frances Wang ^b, Randy L. Jirtle ^c, Joellen M. Schildkraut ^b, Amy P. Murtha ^a, Edwin S. Iversen ^d, Cathrine Hoyo ^{b,**}

^a Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27708, USA

^b Department of Community and Family Medicine, Duke University Medical Center, Durham, NC 27705, USA

^c Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA

^d Department of Statistical Science, Duke University, Durham, NC 27708, USA

ARTICLE INFO

Article history:

Accepted 30 November 2011

Available online 20 December 2011

Received by Suk-Chul Bae

Keywords:

Sex-specific methylation effects

Imprinted gene

Pyrosequencing

Early origins hypothesis

ABSTRACT

Epigenetic alterations may mechanistically explain the developmental origins of adult disease, namely the hypothesis that many complex adult chronic diseases originate as a result of conditions encountered in utero. If true, epigenetically regulated imprinted genes, critical to normal growth and development, may partially mediate these outcomes. We determined the influence of in utero exposure to cigarette smoking on methylation at two differentially methylated regions (DMRs) regulating Insulin-like Growth Factor 2 (*IGF2*) and *H19*, and how this might relate to birth weight of infants born to 418 pregnant women. Smoking status was ascertained through self-report and medical records. Bisulfite pyrosequencing was used to measure methylation in umbilical cord blood DNAs. Least squares DNA methylation means at each DMR and birth weight were compared between infants of smokers and non-smokers, using generalized linear models. While there were no significant differences at the *H19* DMR, infants born to smokers had higher methylation at the *IGF2* DMR than those born to never smokers or those who quit during pregnancy (49.5%, SD = 8.0 versus 46.6%, SD = 5.6 and 45.8%, SD = 6.3, respectively; $p = 0.0002$). The smoking-related increase in methylation was most pronounced in male offspring (p for sex interaction = 0.03), for whom approximately 20% of smoking-related low birth weight was mediated by DNA methylation at the *IGF2* DMR. Our findings suggest that *IGF2* DMR plasticity is an important mechanism by which in utero adjustments to environmental toxicants are conferred. Larger studies to replicate these findings are required.

© 2011 Elsevier B.V. All rights reserved.

1. Introduction

Despite repeated demonstrations of adverse birth outcomes resulting from in utero exposure to cigarette smoking, the prevalence of smoking during pregnancy remains at around 14% in the United States (CDC, 2009). The mechanisms that link exposure to adverse outcomes are poorly understood but appear to be mediated by non-genotoxic adaptations to the gestational environment and/or exposure to toxicants (Barker, 1990; Gluckman et al., 2005). Epidemiologic evidence strongly supports links between conditions encountered

during embryonic or fetal development and adult-onset diseases, including atherosclerosis, coronary heart disease, type 2 diabetes mellitus, obesity, and cancer [for review, see (Godfrey and Barker, 2001)]. These chronic diseases and conditions have also been linked to low birth weight resulting from exposure to both active (Stillman et al., 1986) and passive cigarette smoking during pregnancy (Martin and Bracken, 1986).

Commonly studied non-genotoxic effects are epigenetic mechanisms, including modification of histone proteins and DNA methylation, which have also been hypothesized to explain how in utero exposure to cigarette smoking affects adult-onset diseases. However, the ability to test this hypothesis has been stymied due to the restricted type of biological specimens obtainable from otherwise healthy populations (e.g., peripheral blood, buccal cells) coupled with the lack of identified mitotically stable epigenetic targets that are not substantially influenced by inherent tissue specific differences in methylation.

DNA methylation, the most studied epigenetic mechanism in epidemiologic studies, is typically associated with chromatin condensation through the binding of methyl-CpG binding proteins and

Abbreviations: BMI, body mass index; CI, confidence interval; CpG, cytosine–phosphate–guanine dinucleotide pair; DMR, differentially methylated region; DNA, deoxyribonucleic acid; IGF2, insulin-like growth factor II; GED, general education development diploma; H19, maternally expressed non-coding RNA H19; NEST, Newborn Epigenetics Study; OR, odds ratio; PCR, polymerase chain reaction; SD, standard deviation; SEM, standard error of the mean.

* Correspondence to: S.K. Murphy, Box 91012, Durham, NC 27708, USA. Tel.: +1 919 681 3423; fax: +1 919 684 5336.

E-mail addresses: susan.murphy@duke.edu (S.K. Murphy), hoyo0001@mc.duke.edu (C. Hoyo).

recruitment of proteins involved in chromatin modification that ultimately lead to transcriptional silencing (Portela and Esteller, 2010). DNA methylation regulates genomically imprinted genes through differential marking of the parental alleles during two epigenetic reprogramming events in early pregnancy; in gametogenesis, when methylation is erased and re-established to reflect the sex of the individual in which the developing gametes reside, and after fertilization, when the maternal and paternal pronuclei undergo demethylation and subsequent remethylation that will help guide germ layer specification and tissue differentiation (Feng et al., 2010; Kota and Feil, 2010). We have previously postulated that the mitotic stability of the methylation marks associated with imprinted genes coupled with establishment pre-gastrulation makes them especially suited for epidemiologic study of in utero environmental effects on the epigenome (Hoyo et al., 2009). The inherent plasticity of the epigenome during this period of epigenetic remodeling may allow for adaptive epigenetic profiles to be established at the sequences regulating imprinted genes, modifying gene expression patterns in response to perceived in utero environmental conditions.

The well-characterized imprinted domain at human chromosome 11p15.5 contains paternally expressed Insulin-like Growth Factor II (*IGF2*) and the maternally expressed *H19* gene, from which is transcribed a non-coding RNA. Imprinted expression and transcription of *IGF2* are regulated in large part through the patterns of DNA methylation of at least two differentially methylated regions (DMRs), one of which is located near the *H19* promoter (*H19* DMR) and the other upstream of the three *IGF2* promoters that are subject to imprinting (*IGF2* DMR). Both DMRs have been shown to exhibit altered methylation in cigarette smoking-related malignancies (Cruz-Correa et al., 2004; Cui et al., 2002). In the present study, we examined the influence of in utero exposure to cigarette smoke on DNA methylation at the *IGF2/H19* imprinted domain using umbilical cord blood specimens naïve to the ex utero environment. We furthermore determined the extent to which methylation profiles mediate the link between maternal smoking and low birth weight.

2. Materials and methods

2.1. Study participants

Study participants were enrolled as part of the Newborn Epigenetics Study (NEST), a multiethnic birth cohort designed to identify the effects of early exposures on epigenetic profiles and phenotypic outcomes. These studies were approved by the Duke University Institutional Review Board and written consent was obtained from all mothers participating as study subjects. A detailed description of identification and enrollment procedures has been published elsewhere (Hoyo et al., 2011). Briefly, pregnant women were recruited from prenatal clinics serving Duke University Hospital and Durham Regional Hospital Obstetrics facilities in Durham, North Carolina from April 2005 to June 2008. Eligibility criteria were: age ≥ 18 years, English speaking, pregnant, and intention to use one of the two obstetrics facilities for the index pregnancy to enable access to labor and birth outcome data as well as umbilical cord blood. To ensure an adequate sample size for cigarette exposure, smoking women were targeted for the first ~200 women recruited. Gestational age at enrollment ranged from 19 to 42 weeks. Of the 1101 women approached, 940 (85%) were enrolled. Cord blood samples were collected from 720 infants. Bisulfite pyrosequencing has been completed on the first 428 cord blood samples for the *H19* and *IGF2* DMRs. The 428 participants in whom specimens were available were similar to the 940 enrolled in the study, with respect to maternal age ($p=0.55$) maternal education ($p=0.94$), race/ethnicity ($p=0.39$) and infant sex ($p=0.81$). Six of the 428 were excluded because smoking status could not be defined with certainty; four additional mothers gave conflicting answers to smoking-related questions and

were also excluded. Final analyses included the 418 samples for which smoking and methylation data were available.

2.2. Data collection

At enrollment, a standardized questionnaire was administered that included maternal demographic characteristics, health status, reproductive factors, anthropometric measurements, and lifestyle factors such as tobacco use, alcohol intake and use of dietary supplements. We abstracted medical charts to verify responses to our main exposure and outcomes, cigarette smoking and birth weight.

2.3. Ascertainment of cigarette smoking status

To improve the accuracy of self-reported smoking status, cigarette smoking was ascertained by responses to four questions. First, women were asked to answer “Yes” or “No” to the question, “Before the year you found out you were pregnant, did you smoke?” They were also asked, “After you found out you were pregnant, which of the following best describes your behavior?” The four possible responses were, “I continue to smoke,” or “I stopped during the first/second/third trimester.” To further verify smoking behavior, in two different parts of the questionnaire women were also asked, “Have you ever smoked 100 cigarettes or more in your lifetime?” (Yes/No), followed by, “Do you smoke now?” (Yes/No). Three maternal smoking categories were created as follows: Women were considered “smokers during pregnancy” if they answered affirmatively to ever having smoked 100 cigarettes or more, being a current smoker, and smoking during pregnancy; women were considered “quitters during pregnancy” if they had responded affirmatively to ever smoking 100 cigarettes or more, smoking during the year of pregnancy, and stopping smoking any time during the pregnancy; “non-smokers” were women who responded negatively to ever smoking 100 cigarettes or more, and negatively to current smoking.

2.4. Specimen collection

Immediately following newborn delivery, the umbilical vein was punctured and umbilical cord blood was collected into K₃EDTA-containing vacutainer tubes. The leukocyte-containing buffy coat was isolated following centrifugation at 3500 \times g for 20 min at 4 °C. Aliquots were prepared and stored at -80 °C.

2.5. Other variables

At enrollment, a standardized questionnaire was used to solicit information on maternal age, race/ethnicity, marital status, education, pre-pregnancy weight, and height. Medical records were used to obtain gestational age at enrollment and at delivery, birth weight and infant gender. Body mass index (BMI) was computed by dividing weight by height squared.

2.6. DNA methylation analysis

Genomic DNA from buffy coat specimens was extracted using Genra Puregene Reagents (Qiagen, Valencia, CA). The *IGF2* and *H19* DMRs were analyzed by bisulfite pyrosequencing. Bisulfite modification was performed as previously described (Huang et al., 2006). Pyrosequencing assays were designed using PSQ Assay Design Software and duplicate reactions run on a Pyromark Q96 MD Pyrosequencer (Qiagen). The percent methylation for each of the CpGs within the target sequence was calculated using PyroQ CpG Software (Qiagen). Bisulfite conversion efficiency was assessed using the PyroQ CpG Software and averaged 97.3% (SD = 0.98%) for the *H19* DMR and 99.5% (SD = 2.7%) for the *IGF2* DMR.

Table 1
Maternal and infant characteristics by cigarette-smoking behavior during pregnancy.

Characteristics	Smokers	Quit in pregnancy	Never smoked	Fisher's exact p-value
	(N = 75)	(N = 110)	(N = 222)	
	# (%)	# (%)	# (%)	
Maternal age				
<30 years	49 (65.3)	64 (58.2)	113 (50.9)	0.03
30–39 years	23 (30.7)	39 (35.4)	101 (45.5)	
40 years	3 (4.0)	7 (6.4)	8 (3.6)	
Education				
<High school	50 (66.7)	49 (44.5)	55 (24.9)	<0.0001
High school or <college	19 (25.3)	29 (26.4)	63 (28.5)	
College or more	6 (8.0)	32 (29.1)	103 (46.6)	
Missing	0	0	1	
Race				
African American	41 (54.7)	51 (46.4)	110 (49.5)	0.2
White	33 (44.0)	49 (44.5)	93 (41.9)	
Asian/Hispanic/other/missing	1 (1.3)	10 (9.1)	19 (8.6)	
Marital status				
Single	30 (40.0)	26 (23.6)	67 (30.2)	0.05
Married/partner	36 (48.0)	70 (63.6)	148 (66.7)	
Divorce/widowed	9 (12.0)	14 (12.7)	7 (3.2)	
BMI				
<25	29 (46.8)	50 (50.0)	110 (53.1)	0.4
25–29	17 (27.4)	18 (18.0)	41 (19.8)	
30–34	10 (16.1)	13 (13.0)	25 (12.1)	
35+	6 (9.7)	19 (19.0)	31 (15.0)	
Missing	13	10	15	
Gestational age at birth				
≤36 weeks	14 (18.7)	15 (13.6)	29 (13.1)	0.03
>36 weeks	61 (81.3)	95 (86.4)	193 (86.9)	
Birth weight				
<2500 g	18 (24.3)	16 (14.7)	23 (10.4)	<0.0001
≥2500 g	56 (75.7)	93 (85.3)	197 (89.6)	
Missing	1	1	2	
Offspring sex				
Female	34 (47.2)	52 (48.6)	107 (48.6)	0.8
Male	38 (52.8)	55 (51.4)	113 (51.4)	
Missing	3	3	2	
5-minute Apgar score				
0–8	5 (6.9)	16 (15.8)	27 (12.9)	0.7
9–10	68 (93.1)	85 (84.2)	182 (87.1)	
Missing	2	9	13	

The region analyzed for the *IGF2* DMR includes three CpG dinucleotides upstream of exon 3 (chr 11p15.5; CpG site 1: 2,169,518; CpG site 2: 2,169,515; and CpG site 3: 2,169,499; NCBI Human Genome Build 37/hg19) (Cui et al., 2002). The region studied for the *H19* DMR encompasses four dinucleotides located upstream of the *H19* gene (chr 11p15.5; CpG site 1: 2,024,261, CpG site 2: 2,024,259, CpG site 3: 2,024,257, and CpG site 4: 2,024,254; NCBI Human Genome Build 37/hg19), which are located within one of the six CTCF binding sites of this region (Cui et al., 2001).

For the *IGF2* DMR, 50 ng of bisulfite-modified DNA was amplified using 2U Platinum Taq DNA polymerase (Invitrogen, Carlsbad, CA) and 0.15 μM each forward (5'-GGA GGG GGT TTA TTT TAG GAA G-3') and reverse (5'-[Biotin]-AAC CCC AAC AAA AAC CAC TAA ACA C-3') primers in a 40 μl reaction volume with 0.2 mM dNTPs and 3 mM MgCl₂. PCR conditions were 94 °C for 3 m, then 5 cycles of 94 °C for 30 s, 70 °C for 30 s, 72 °C for 30 s; then 5 cycles of 94 °C for 30 s, 68 °C for 30 s, 72 °C for 30 s; then 50 cycles of 94 °C for 30 s, 66 °C for 30 s, 72 °C for 30 s; followed by a 5 m extension at 72 °C. Biotin-labeled single-stranded amplicons were isolated according to protocol using the Qiagen Pyromark Q96 Work Station and underwent pyrosequencing with 0.5 μM primer 5'-GGG GTT TAT TTT TTT AGG A-3'.

For the *H19* DMR, 40 ng of bisulfite-modified DNA was amplified using 1U Platinum Taq DNA polymerase and 0.15 μM each forward (5'-TTT GTT GAT TTT ATT AAG GGA G-3') and reverse (5'-[Biotin]CTA TAA ATA AAC CCC AAC CAA AC-3') primers in a 20 μl reaction volume with 0.1 mM dNTPs and 3 mM MgCl₂. PCR conditions were 94 °C for 3 m, then 5 cycles of 94 °C for 30 s, 65 °C for 30 s, 72 °C for 30 s; then

5 cycles of 94 °C for 30 s, 62 °C for 30 s, 72 °C for 30 s; then 35 cycles of 94 °C for 30 s, 59 °C for 30 s, 72 °C for 30 s; followed by a 5 m extension at 72 °C. The biotin-labeled single-stranded amplicons were isolated as described above and underwent pyrosequencing using 0.5 μM of primer 5'-GTG TGG AAT TAG AAG T-3'.

Assay validation was performed by analysis of defined ratios of plasmids that contain inserts derived from the bisulfite modified version of the methylated and unmethylated sequences, as previously described (Wong et al., 2006).

2.7. Statistical analysis

Covariates considered as potential confounders or effect modifiers are included in Table 1 and included maternal age (<30 years, 30–39 years, >40+ years), body mass index (BMI; kg/m²) before pregnancy, cigarette smoking (never smoked, smoked during early pregnancy but stopped, or current smoker), gestational age (<37 weeks or ≥37 weeks), birth weight (<2500 g [low] or ≥2500 g [normal]), gender of the offspring (male or female), mother's education (less than high school, high school/GED, some college, college graduate, or graduate education), and mother's race/ethnicity (African American, Caucasian or other).

DMR methylation percentages at each CpG dinucleotide were evaluated for normal distribution using Kolmogorov–Smirnov tests. Principal components and confirmatory factor analyses were then used to determine whether methylation at the individual CpGs analyzed at the *IGF2* and *H19* DMRs were correlated enough for each

region to be represented by a single mean. The values for Cronbach's alpha, a measure of internal consistency, for the CpGs were 86% and 87% at the *IGF2* DMR and *H19* DMR, respectively. These high correlations at each DMR justified the use of a single mean for each DMR.

We used chi-square tests to determine whether categorical maternal and offspring characteristics varied by maternal cigarette smoking. F-tests from generalized linear models (PROC GLM) were used to compare unadjusted and adjusted least squares mean methylation levels of infants born to women who reported continuing to smoke during pregnancy to those of women who 1) never smoked and 2) stopped smoking during pregnancy. We also employed logistic regression models to confirm the association between cigarette smoking and low birth weight, and to estimate the percent of smoking-related low birth weight mediated by aberrant *IGF2* methylation. In such analyses, aberrant methylation at the *IGF2* DMR was dichotomized as the methylation in the lowest quartile of the distribution, given that hypomethylation at this DMR has been linked to loss of genomic imprinting (Cui et al., 2003) and periconceptional caloric restriction (Heijmans et al., 2008). Although we considered, for potential confounding, factors that were associated with birth weight, rapid growth or childhood obesity in the population and in our data set in Table 1 ($-value < 0.25$) one at a time, we retained only maternal education, gestational age, birth weight, race/ethnicity and BMI before pregnancy entered as continuous and categorical variables (Table 1), as these factors contributed significantly to the model ($p < 0.05$).

Because early exposures have been shown to influence the *IGF2* methylation profiles differently by sex (Heijmans et al., 2008), and because epigenetic response may vary by genetic factors (Waterland et al., 2010), we repeated these analyses stratified by sex and race. To allow for unrestrained model entry of individual CpGs into statistical models, we repeated the above using mixed effects models. Finally, we conducted mediation analyses to determine the extent to which the association between maternal cigarette smoking and low birth weight was mediated by methylation at either the *H19* or *IGF2* DMR using standard methods as described (Baron and Kenny, 1986).

3. Results

The average gestational age at enrollment was 22 weeks (range 19 to 42 weeks). Although smokers were targeted for the first ~200 recruited, the majority of pregnant women (55%) had never smoked, 27% reported they had stopped smoking during the first trimester, and 18% were smokers at enrollment. Of the 110 women who quit smoking during pregnancy, 52 (47%) quit during the first trimester, 14 (13%) quit during the second trimester, and 7 (6%) quit during the third trimester. The remaining 37 women (33%) did not report the time during pregnancy that they quit smoking. Women who smoked during pregnancy and those who stopped smoking early in pregnancy did not significantly differ from never smokers by maternal age, alcohol intake, race, obesity status, gestational age at birth, sex or Apgar score of the offspring (Table 1). However, only 48% ($n = 36$) of women who smoked compared to 67% ($n = 148$) of women who never smoked were married or lived with a partner ($p < 0.001$). Smokers and non-smokers also differed by educational attainment; just 25% ($n = 55$) of non-smokers but 67% ($n = 50$) of smokers had less than a high school education ($p < 0.001$). As expected, infants born to smokers were two times more likely to weigh less than 2500 g at birth compared to offspring of women who reported never smoking ($p = 0.001$). Hence, in subsequent analysis, we assessed for potential confounding by maternal education, marital status, gestational age and birth weight as well as infant's sex, maternal BMI before pregnancy and race/ethnicity as the latter factors have been associated with methylation patterns and/or birth weight in other studies (Adkins et al., 2011).

Table 2

Methylation fractions at the *IGF2*/*H19* imprinted domain by maternal cigarette smoking during pregnancy.

	Pregnancy-related smoking behavior			Methylation differences between current smokers and those who	
	Smokers	Quit in pregnancy	Never smoked	Quit in pregnancy	Never smoked
	(n = 75)	(n = 110)	(n = 222)	(p-value)	(p-value)
<i>H19</i> _CG1	59.84	60.13	59.82	0.29 (0.8)	-0.01 (1.0)
<i>H19</i> _CG2	56.81	57.50	57.58	0.68 (0.6)	0.77 (0.5)
<i>H19</i> _CG3	59.27	60.08	59.43	0.80 (0.5)	0.16 (0.9)
<i>H19</i> _CG4	58.68	59.53	58.91	0.85 (0.5)	0.23 (0.9)
<i>H19</i> mean	58.65	59.31	58.94	0.66 (0.6)	0.29 (0.8)
	Smokers	Quit in pregnancy	Never smoked	Quit in pregnancy	Never smoked
	(n = 63)	(n = 86)	(n = 178)	(p-value)	(p-value)
<i>IGF2</i> _CG1	45.61	40.56	41.13	-5.05 (0.0003)	-4.48 (0.001)
<i>IGF2</i> _CG2	54.17	50.74	51.44	-3.43 (0.0006)	-2.73 (0.01)
<i>IGF2</i> _CG3	53.90	49.14	49.31	-4.76 (0.0004)	-4.59 (0.0005)
<i>IGF2</i> mean	49.50	45.86	46.64	-3.63 (0.001)	-2.86 (0.002)

Means adjusted for maternal education, gestational age, maternal body mass index before pregnancy, race/ethnicity, offspring's sex, birth weight.

Overall, DNA methylation means were 61.2% (SD = 4.2%) and 47.3% (SD = 4.5%) at the *H19* and *IGF2* DMRs, respectively, and were similar at each CpG dinucleotide. Table 2 shows methylation percentages for each CpG evaluated, and the average methylation levels at each DMR in offspring of smokers and non-smokers. Infants born to women who never smoked had a slightly lower methylation fraction on average (46.6%) when compared to infants of women who either quit during pregnancy or continued to smoke (47.8%). However, when pregnant smokers were categorized into two groups including those who quit smoking during pregnancy and those who continued to smoke, we found that infants born to women who continued to smoke during pregnancy had a 3.6% ($p = 0.001$) and 2.9% ($p = 0.002$) higher mean methylation fraction at the *IGF2* DMR (49.5%, SD = 8.0; $n = 63$) than infants born to women who stopped smoking in pregnancy (45.8%, SD = 6.3; $n = 86$) or infants born to women who never smoked (46.6, SD = 5.6%; $n = 178$; $p = 0.002$; Table 2). These differences were adjusted for maternal BMI before pregnancy, race/ethnicity, education, gestational age, sex, and birth weight. This significant difference persisted at each of the three CpG dinucleotides evaluated. Neither modeling these relationships using mixed effects models to allow unconstrained model entry of each CpG dinucleotide, nor estimating unadjusted DNA methylation differences altered these findings. Removal of the 10 observations with very low or high DNA methylation also did not alter these findings. However, at the *H19* DMR, methylation differences were not apparent among the 75 infants born to women who continued to smoke during pregnancy and the 110 born to those who stopped in early pregnancy ($p = 0.8$) or those born to 222 women who never smoked ($p = 0.8$).

As noted previously, several lines of evidence suggest that adverse environmental effects such as exposure to cadmium (Tellez-Plaza et al., 2010) or severe caloric restriction (Heijmans et al., 2008) are gender-dependent. We therefore stratified our analyses by sex of the infant. At the *IGF2* DMR, we found no methylation differences in female infants born to women who continued to smoke during pregnancy ($n = 34$) and those who either never smoked ($n = 107$) (0.6%, $p = 0.7$) or those who stopped smoking after pregnancy began ($n = 52$) (0.9%, $p = 0.5$). However, among males, those born to women who stopped smoking during pregnancy had 6.5% lower methylation ($n = 55$; $p = 0.0001$) while those born to women who never smoked had 4.7% lower methylation ($n = 117$; $p = 0.0002$),




Fig. 1. Percent differences in methylation at the *H19* and *IGF2* DMRs in male and female infants in relation to maternal smoking status during pregnancy. For each DMR, the average difference in methylation is shown (\pm SEM) on the y-axis for male and female infants born to mothers who quit smoking during pregnancy (gray bars) or never smoked cigarettes (white bars) as compared to infants born to mothers who smoked throughout pregnancy (current smokers; baseline methylation). There was no significant difference at the *H19* DMR for $n=206$ males (quit: -0.8% methylation difference, $p=0.61$; never: -2.4% methylation difference, $p=0.13$) or $n=193$ females (quit: $+1.9\%$ methylation difference, $p=0.32$; never: $+1.1\%$ methylation difference, $p=0.54$). The *IGF2* DMR also showed no significant difference for $n=151$ females (quit: -0.6% methylation difference, $p=0.73$; never: -0.9% methylation difference, $p=0.51$) while male infants ($n=169$) born to current smokers showed significantly elevated methylation relative to those born to mothers who quit smoking during pregnancy (-6.5% difference, $p<0.0001$) and those born to mothers who never smoked (-4.7% methylation difference, $p=0.0002$).

than those born to women who continued to smoke during pregnancy ($n=38$; Fig. 1). Neither analyses unadjusted for potential confounders nor mixed models altered these findings (data not shown). The interaction term for infant sex and maternal smoking during pregnancy that was included in the final models was statistically significant ($p=0.03$).

We also computed odds ratios for the association between low birth weight and cigarette smoking, and estimated the proportion of smoking-related low birth weight that is mediated by variation in *IGF2* DMR methylation. After adjusting for potential confounding factors, we found an over four-fold increase in the risk of low birth weight associated with continued maternal cigarette smoking (OR=4.16, 95% CI=1.44–11.99). These analyses revealed that 21% of the association between maternal cigarette smoking and low birth weight in male infants was mediated by aberrant methylation the *IGF2* DMR, compared to 2.2% in female infants (Table 3).

4. Discussion

In the present study, we tested the hypothesis that maternal cigarette smoking is associated with changes in DNA methylation at two DMRs regulating the expression of *H19* and *IGF2*, and that methylation profiles mediate the association between maternal cigarette smoking and low birth weight. While no associations were found between *H19* DMR methylation and maternal cigarette smoking, we

found significantly higher *IGF2* DMR methylation in infants born to women who smoked throughout pregnancy when compared to those who either stopped smoking during pregnancy or those who never smoked. Methylation differences were most apparent in male infants. Approximately 21% of smoking-related low birth weight (with smoking defined as either continued to smoke during pregnancy or quit in early pregnancy) was mediated by aberrant *IGF2* methylation in males compared to 2% in female infants.

Our findings support earlier studies showing that the effects of in utero tobacco smoke exposure may at least partially be mediated through alterations in DNA methylation (Breton et al., 2009). These results therefore support the interpretation that epigenetic plasticity is an important mechanism by which early adaptations to environmental cues such as cigarette smoking are realized. Some (Heijmans et al., 2008) but not all (Waterland et al., 2010) have found methylation differences at the *IGF2* DMR between individuals exposed and not exposed to environmental stimuli such as nutrient challenges, suggesting that this DMR is a reasonable epigenetic biosensor for evaluating early environmental exposures (Hoyo et al., 2009). Deregulation of *IGF2* expression has been linked to overgrowth disorders (Delaval et al., 2006; Morison and Reeve, 1998; Riccio et al., 2009), obesity (Gomes et al., 2005; Roth et al., 2002) and cancer (Byun et al., 2007; Chao and D'Amore, 2008; Cui et al., 2003; Ito et al., 2008; Murphy et al., 2006; Paradowska et al., 2009; Pollak, 2008; Raveln et al., 2001; Shetty et al., 2010; Sullivan et al., 1999; Taniguchi et al., 1995; Xu et al., 2006; Zuo et al., 2011). We (Hoyo et al., 2009) and others (Heijmans et al., 2009; Mathers, 2007) have proposed that methylation shifts at sequences regulating genomic imprinting can serve as archives of the periconceptual and prenatal environment.

Methylation differences observed in this study are small when compared to those found in studies of animal exposure (Dolinoy et al., 2007) or in human pathology (Cui, 2007; Ito et al., 2008; Murphy et al., 2006; Murrell et al., 2008; Sullivan et al., 1999; Xu et al., 2006). However, this should be expected, given the exposure heterogeneity of human populations combined with an apparent intolerance for sustained dramatic shifts in methylation, especially at this locus, which are often associated with malignancy. To gain insights into the functional significance of methylation differences observed, we explored our unpublished gene expression microarray data (Affymetrix U133 HTA platform) for 41 infants included in this study to

Table 3

^aOdds ratios for the association between maternal smoking and birth weight among 323 newborns.

Characteristic	OR (95% CI)
Smoking vs. never	4.16 (1.44, 11.99)
Quit vs. never	1.70 (0.60, 4.85)
<i>IGF2</i> DMR mean methylation (<25th percentile)	0.82 (0.30, 2.24)
Race	
African Americans vs. others	6.52 (0.48, 88.59)
Whites vs. others	1.80 (0.14, 23.45)
Sex (male vs. females)	0.61 (0.25, 1.50)
Gestational age <36 wks vs. ≥ 36 wks	27.05 (9.48, 77.18)
Marital status (single vs. widow)	1.52 (0.18, 13.17)
Not single vs. widow	2.23 (0.30, 16.50)

^a Factors mutually adjusted for each other.

determine the relationship between *IGF2* expression (*IGF2* probe 202409_at) and methylation at the *IGF2* DMR. Although the correlation coefficient was in the expected direction ($\rho = -0.20$), it was not statistically significant ($p = 0.22$), likely owing to small sample size. Nevertheless, these data suggest that for every 1% decrease in methylation, there is an approximate two-fold increase in *IGF2* transcription (Supplementary Fig. 1), theoretically equivalent to what would be observed if the maternal allele was aberrantly activated, as is seen with loss of imprinting. Thus, a 5% decrease in methylation at the *IGF2* DMR is associated with an approximate 32-fold increase in *IGF2* expression levels.

The magnitude of the effect on aberrant methylation in our study is strikingly similar to the 4.5% methylation difference reported at the *IGF2* DMR in 17-month old Dutch children exposed to FA during periconception versus those unexposed to FA, as well as the differences that were found in 60 year old adults who were periconceptionally exposed to the Dutch famine of 1944–45. As adults, Dutch famine survivors are at significantly higher risk of neurological disorders, (Anon., 1998) obesity in early and late adulthood, (Ravelli et al., 1976; Ravelli et al., 1999) breast cancer, (Elias et al., 2004b) infertility, (Elias et al., 2004a) and metabolic disorders that include type-2 diabetes and dyslipidemia (Barker, 2004; Gluckman et al., 2007; Painter et al., 2005; Yajnik, 2004). Modest aberrant methylation changes at the *H19* or *IGF2* DMR have been associated with increased expression of *IGF2* (Cui et al., 2001, 2002; Murphy and Jirtle, 2003; Murphy et al., 2006; Murrell et al., 2008; Nakagawa et al., 2001; Sullivan et al., 1999; Takai et al., 2001; Takano et al., 2000; Xu et al., 2006) and increased susceptibility to several chronic diseases (Cruz-Correa et al., 2004; Cui et al., 2003; Feinberg, 2007; Jirtle and Skinner, 2007; Murphy et al., 2006). Equally small effect sizes have been observed in abused children (McGowan et al., 2009) and in individuals conceived using assisted reproductive technologies (Katari et al., 2009). These studies support the idea that, while major epigenetic shifts at imprint regulatory elements may be lethal, adaptive responses to the perceived environment are likely to involve more subtle epigenetic changes.

Our findings do not support the hypothesis that methylation changes at the *IGF2* DMR are limited to the periconceptional period. In our sample, methylation levels in the offspring of non-smokers were indistinguishable from those of women who quit smoking during pregnancy, although this may also reflect unmeasured environmental tobacco smoke among women who never smoked. Although the exact mechanism by which cigarette smoking induces alterations in methylation profiles remains unknown, the nicotine in inhaled tobacco smoke has been shown to be vasoconstrictive in humans (Xiao et al., 2007). Vasoconstriction may limit nutrient flow to the growing fetus, mimicking the effects of caloric restriction previously linked to epigenetic perturbation at this locus (Heijmans et al., 2008).

Our study results suggest, for the first time, that the epigenetic effects of maternal cigarette smoking during pregnancy may be more pronounced in males than in females. The finding that males may be more susceptible to environmental toxicants is supported by recent studies of human conceptuses in abortions and stillbirths showing that the male embryo may be more vulnerable than the female to abnormal methylation (Pliushch et al., 2010). Sex differences in DNA methylation patterns in response to caloric restriction have also been previously reported among Dutch famine victims (Heijmans et al., 2007). Other studies of population-wide human disasters have revealed excess phenotypic response and risk among males (Catalano et al., 2005; Khashan et al., 2011). Although the mechanisms that give rise to these effects are unknown, sex effects could reflect differences in epigenetic mechanisms that are responsive to environmental cues. Alternatively, early adaptations resulting from the effects of maternal cigarette smoke may be similar in male and female fetuses, but malleability following changes in exposure (such as

quitting) may be male-specific. While speculative, these hypotheses may be testable in other birth cohorts.

Although our findings support the hypothesis that maternal cigarette smoking is associated with epigenetic changes at DMRs regulating the imprinted expression of *IGF2*, the direction of the association is dissimilar to that of the Dutch famine studies. Whereas exposure to caloric restriction was associated with hypomethylation at the *IGF2* DMR (Heijmans et al., 2008), we found increases in methylation at this DMR in relation to maternal cigarette smoking. Similarly, in a study of 17-month-old children, investigators reported an increase in methylation in response to folic acid taken during the periconceptional period, and suggested that folic acid improved a hypomethylated state at the *IGF2* DMR, presumably restoring genomic imprinting (Stegers-Theunissen et al., 2009). These findings could not be confirmed in a study of individuals conceived during the nutritionally challenging rainy season in a Gambian rural community (Waterland et al., 2010).

We contend that the periconceptional period represents a particularly vulnerable time period, not only for establishment of the epigenome through epigenetic reprogramming, but also for beneficial or deleterious epigenetic responses to exposures such as cigarette smoking. For example, the in utero environment for infants of smokers and quitters during pregnancy is similar with regard to tobacco smoke exposure at the time of periconception, giving rise to similar DNA methylation profiles at *IGF2* and perhaps other imprinted DMRs. However, epigenetic profiles in infants born to quitters may trigger compensatory measures at the cessation of exposure which counter increased methylation, and this may lead to over-compensation and a lower methylation profile than that observed in the women who did not smoke. In contrast, infants born to those who continued to smoke throughout pregnancy sustained the high level of methylation due to the continued effects of the exposure, and at some point during gestation these patterns become stable and may always be maintained in the offspring. Alternatively, DNA demethylation pathways involving TET-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine (5-hmC) and AID/TDG-mediated base excision repair to replace 5-hmC with cytosine, combined with an inability to distinguish 5-mC from 5-hmC using current technologies, may miss smoking status-related differences in the abundance of these modified bases at these regions. For example, the continuous smoking group may have increased methylation at the *IGF2* DMR based on pyrosequencing, but this could represent an increase in 5-hmC and/or lack of ability to undergo TDG-mediated base excision repair. While speculative, technological advances should clarify the underlying mechanisms.

Major strengths of our study include the large sample size and the use of quantitative methods of analysis for DNA methylation (Heijmans et al., 2007). Pyrosequencing methodology has the capacity to detect subtle differences that have the potential to increase susceptibility to chronic disease in later life. Another strength of our analysis is the focus on the DMR regulating *IGF2*, one of the best-characterized imprinted genes to date, and one with important roles in early embryonic and fetal growth. Finally, because cigarette smoking is a relatively common prenatal exposure, with approximately 10–20% of pregnant women reporting smoking in the United States (Tong et al., 2009) the finding that prenatal cigarette smoke exposure may be an important in utero effector of epigenetic profiles is significant. If our findings are confirmed by others, interventions aimed at smoking cessation during pregnancy, as monitored by methylation profiles in the offspring, offers the potential for identifying nutrients that can negate these effects. Such findings could have a dramatic public health and therapeutic impact on preventing adverse long-term health consequences of these epigenetic alterations.

A limitation of our study is the evaluation of DNA methylation at only two DMRs in the *IGF2/H19* imprinted domain. We chose to focus specifically on this region because it is clear that *IGF2* plays a

fundamental role in regulating growth and because expression of IGF2 is deregulated in many disorders and diseases. As compared to other human imprinted domains, methylation at the *IGF2/H19* imprinted domain is very well characterized as is involvement of methylation changes at these DMRs in regulating imprint status and levels of *IGF2* expression. Another limitation relates to our ascertainment of maternal smoking status. Although women were asked four different questions to determine past and current smoking behavior, and medical records were used to verify smoking status, it is possible that some smokers were misclassified. Cigarette smoking is particularly vulnerable to misclassification because smoking while pregnant is a socially undesirable behavior. However, because women were unaware of the study hypothesis and we verified exposure using medical records, we expect misclassification in this cohort to be minimal. Moreover, women are unlikely to affirm smoking status if they do not smoke. In the event that some cigarette smoking was misclassified, it is unlikely that such misclassification would differ by methylation fraction or other newborn characteristics. Non-differential misclassification, if it exists, would likely attenuate the differences observed. This vulnerability to misclassification also resulted in the suboptimal response to questions on the timing when women stopped smoking, relative to when the pregnancy began, and the number of cigarettes smoked per day. These limitations in smoking ascertainment precluded evaluation of the effects of quitting smoking before the pregnancy began separately from never smoking, as well as intensities of smoking on the epigenetic profile.

4.1. Conclusions

Despite these limitations, we provide the first evidence for smoking-related, subtle but stable methylation shifts in utero, offering a potential explanation for the increased frequency of low birth weight infants born to women who smoke during pregnancy. We found that maternal cigarette smoking differentially alters *IGF2*-regulating methylation in a manner depending on infant sex, and that up to 20% of smoking-related low birth weight is mediated by methylation shifts at this DMR. This initial evidence for *IGF2* DMR plasticity provides a potential explanation for higher susceptibility to toxins in males. The methylation target identified in this study could be further developed as a biosensor for public health or therapeutic interventions aimed at ameliorating the phenotypic consequences of in utero exposure to cigarette smoking.

Author's contributions

C.H. and S.K.M. conceived and designed the study, C.H., S.K.M., Z.H., F.O. and A.P.M. acquired and/or generated data, C.H., F.W., S.K.M., Z.H., J.S.S., R.L.J. and E.S.I. contributed to data analysis and interpretation, A.A., S.K.M. and C.H. drafted the manuscript, C.H., S.K.M., A.A., Z.H., J.S.S., R.L.J., A.P.M. and E.S.I. helped to revise the manuscript, and all authors provided final approval of the manuscript.

Supplementary materials related to this article can be found online at doi:10.1016/j.gene.2011.11.062.

Acknowledgments

This research was supported by National Institutes of Health grants R21ES014947, R01ES016772, R01DK085173 and by funding from the Duke Comprehensive Cancer Center.

References

Adkins, R.M., Thomas, F., Tylavsky, F.A., Krushkal, J., 2011. Parental ages and levels of DNA methylation in the newborn are correlated. *BMC Med. Genet.* 12, 47.
Anon., 1998. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Expert Panel on the

Identification, Evaluation, and Treatment of Overweight in Adults. *Am. J. Clin. Nutr.* 68, 899–917.
Barker, D.J., 1990. The fetal and infant origins of adult disease. *BMJ* 301, 1111.
Barker, D.J., 2004. The developmental origins of adult disease. *J. Am. Coll. Nutr.* 23, 588S–595S.
Baron, R.M., Kenny, D.A., 1986. The moderator–mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. *J. Personal. Soc. Psychol.* 51, 1173–1182.
Breton, C.V., Byun, H.M., Wenten, M., Pan, F., Yang, A., Gilliland, F.D., 2009. Prenatal tobacco smoke exposure affects global and gene-specific DNA methylation. *Am. J. Respir. Crit. Care Med.* 180, 462–467.
Byun, H.M., Wong, H.L., Birnstein, E.A., Wolff, E.M., Liang, G., Yang, A.S., 2007. Examination of *IGF2* and *H19* loss of imprinting in bladder cancer. *Cancer Res.* 67, 10753–10758.
Catalano, R., Bruckner, T., Gould, J., Eskenazi, B., Anderson, E., 2005. Sex ratios in California following the terrorist attacks of September 11, 2001. *Hum. Reprod.* 20, 1221–1227.
CDC, 2009. Trends in Smoking before, during, and after pregnancy – Pregnancy Risk Assessment Monitoring System (PRAMS), United States, 31 Sites, 2000–2005. *Surveill. Summ.* SS-4.
Chao, W., D'Amore, P.A., 2008. IGF2: epigenetic regulation and role in development and disease. *Cytokine Growth Factor Rev.* 19, 111–120.
Cruz-Correa, M., et al., 2004. Loss of imprinting of insulin growth factor II gene: a potential heritable biomarker for colon neoplasia predisposition. *Gastroenterology* 126, 964–970.
Cui, H., 2007. Loss of imprinting of *IGF2* as an epigenetic marker for the risk of human cancer. *Dis. Markers* 23, 105–112.
Cui, H., et al., 2001. Loss of imprinting of insulin-like growth factor-II in Wilms' tumor commonly involves altered methylation but not mutations of CTCF or its binding site. *Cancer Res.* 61, 4947–4950.
Cui, H., Onyango, P., Brandenburg, S., Wu, Y., Hsieh, C.L., Feinberg, A.P., 2002. Loss of imprinting in colorectal cancer linked to hypomethylation of *H19* and *IGF2*. *Cancer Res.* 62, 6442–6446.
Cui, H., et al., 2003. Loss of *IGF2* imprinting: a potential marker of colorectal cancer risk. *Science* 299, 1753–1755.
Delaval, K., Wagschal, A., Feil, R., 2006. Epigenetic deregulation of imprinting in congenital diseases of aberrant growth. *Bioessays* 28, 453–459.
Dolinoy, D.C., Huang, D., Jirtle, R.L., 2007. Maternal nutrient supplementation counteracts bisphenol A-induced DNA hypomethylation in early development. *Proc. Natl. Acad. Sci. U. S. A.* 104, 13056–13061.
Elias, S.G., et al., 2004a. Urinary endogenous sex hormone levels in postmenopausal women after caloric restriction in young adulthood. *Br. J. Cancer* 90, 115–117.
Elias, S.G., Peeters, P.H., Grobbee, D.E., van Noord, P.A., 2004b. Breast cancer risk after caloric restriction during the 1944–1945 Dutch famine. *J. Natl. Cancer Inst.* 96, 539–546.
Feinberg, A.P., 2007. An epigenetic approach to cancer etiology. *Cancer J.* 13, 70–74.
Feng, S., Jacobsen, S.E., Reik, W., 2010. Epigenetic reprogramming in plant and animal development. *Science* 330, 622–627.
Gluckman, P.D., Cutfield, W., Hofman, P., Hanson, M.A., 2005. The fetal, neonatal, and infant environments—the long-term consequences for disease risk. *Early Hum. Dev.* 81, 51–59.
Gluckman, P., Hanson, M., Beedle, A., 2007. Early life events and their consequences for later diseases: a life history and evolutionary perspective. *Am. J. Hum. Biol.* 19.
Godfrey, K.M., Barker, D.J., 2001. Fetal programming and adult health. *Public Health Nutr.* 4, 611–624.
Gomes, M.V., Soares, M.R., Pasqualim-Neto, A., Marcondes, C.R., Lobo, R.B., Ramos, E.S., 2005. Association between birth weight, body mass index and *IGF2*/Apal polymorphism. *Growth Horm. IGF Res.* 15, 360–362.
Heijmans, B.T., Kremer, D., Tobi, E.W., Boomsma, D.I., Slagboom, P.E., 2007. Heritable rather than age-related environmental and stochastic factors dominate variation in DNA methylation of the human *IGF2/H19* locus. *Hum. Mol. Genet.* 16, 547–554.
Heijmans, B.T., et al., 2008. Persistent epigenetic differences associated with prenatal exposure to famine in humans. *Proc. Natl. Acad. Sci. U. S. A.* 105, 17046–17049.
Heijmans, B.T., Tobi, E.W., Lumey, L.H., Slagboom, P.E., 2009. The epigenome: archive of the prenatal environment. *Epigenetics* 4, 526–531.
Hoyo, C., Murphy, S.K., Jirtle, R.L., 2009. Imprint regulatory elements as epigenetic biosensors of exposure in epidemiological studies. *J. Epidemiol. Community Health* 63, 683–684.
Hoyo, C., et al., 2011. Folic acid supplementation before and during pregnancy in the Newborn Epigenetics Study (NEST). *BMC Publ. Health* 11, 46.
Huang, Z., Wen, Y., Shandilya, R., Marks, J.R., Berchuck, A., Murphy, S.K., 2006. High throughput detection of *MGP/IGF2R* intronic hypermethylation and LOH in ovarian cancer. *Nucleic Acids Res.* 34, 555–563.
Ito, Y., et al., 2008. Somatic acquired hypomethylation of *IGF2* in breast and colorectal cancer. *Hum. Mol. Genet.* 17, 2633–2643.
Jirtle, R.L., Skinner, M.K., 2007. Environmental epigenomics and disease susceptibility. *Nat. Rev. Genet.* 8, 253–262.
Katari, S., et al., 2009. DNA methylation and gene expression differences in children conceived in vitro or in vivo. *Hum. Mol. Genet.* 18, 3769–3778.
Khashan, A.S., et al., 2011. Risk of affective disorders following prenatal exposure to severe life events: a Danish population-based cohort study. *J. Psychiatr. Res.* 45, 879–885.
Kota, S.K., Feil, R., 2010. Epigenetic transitions in germ cell development and meiosis. *Dev. Cell* 19, 675–686.
Martin, T.R., Bracken, M.B., 1986. Association of low birth weight with passive smoke exposure in pregnancy. *Am. J. Epidemiol.* 124, 633–642.

- Mathers, J.C., 2007. Early nutrition: impact on epigenetics. *Forum Nutr.* 60, 42–48.
- McGowan, P.O., et al., 2009. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. *Nat. Neurosci.* 12, 342–348.
- Morison, I.M., Reeve, A.E., 1998. Insulin-like growth factor 2 and overgrowth: molecular biology and clinical implications. *Mol. Med. Today* 4, 110–115.
- Murphy, S.K., Jirtle, R.L., 2003. Imprinting evolution and the price of silence. *Bioessays* 25, 577–588.
- Murphy, S.K., et al., 2006. Frequent *IGF2/H19* domain epigenetic alterations and elevated *IGF2* expression in epithelial ovarian cancer. *Mol. Cancer Res.* 4, 283–292.
- Murrell, A., et al., 2008. Distinct methylation changes at the *IGF2-H19* locus in congenital growth disorders and cancer. *PLoS One* 3, e1849.
- Nakagawa, H., Chadwick, R.B., Peltomaki, P., Plass, C., Nakamura, Y., de La Chapelle, A., 2001. Loss of imprinting of the insulin-like growth factor II gene occurs by biallelic methylation in a core region of *H19*-associated CTCF-binding sites in colorectal cancer. *Proc. Natl. Acad. Sci. U. S. A.* 98, 591–596.
- Painter, R.C., Roseboom, T.J., Bleker, O.P., 2005. Prenatal exposure to the Dutch famine and disease in later life: an overview. *Reprod. Toxicol.* 20, 345–352.
- Paradowska, A., et al., 2009. Aberrant epigenetic modifications in the CTCF binding domain of the *IGF2/H19* gene in prostate cancer compared with benign prostate hyperplasia. *Int. J. Oncol.* 35, 87–96.
- Pliushch, G., et al., 2010. Extreme methylation values of imprinted genes in human abortions and stillbirths. *Am. J. Pathol.* 176, 1084–1090.
- Pollak, M., 2008. Insulin and insulin-like growth factor signalling in neoplasia. *Nat. Rev. Cancer* 8, 915–928.
- Portela, A., Esteller, M., 2010. Epigenetic modifications and human disease. *Nat. Biotechnol.* 28, 1057–1068.
- Ravelli, G.P., Stein, Z.A., Susser, M.W., 1976. Obesity in young men after famine exposure in utero and early infancy. *N. Engl. J. Med.* 295, 349–353.
- Ravelli, A.C., van Der Meulen, J.H., Osmond, C., Barker, D.J., Bleker, O.P., 1999. Obesity at the age of 50 y in men and women exposed to famine prenatally. *Am. J. Clin. Nutr.* 70, 811–816.
- Ravenel, J.D., et al., 2001. Loss of imprinting of insulin-like growth factor-II (*IGF2*) gene in distinguishing specific biologic subtypes of Wilms tumor. *J. Natl. Cancer Inst.* 93, 1698–1703.
- Riccio, A., et al., 2009. Inherited and sporadic epimutations at the *IGF2-H19* locus in Beckwith–Wiedemann syndrome and Wilms' tumor. *Endocr. Dev.* 14, 1–9.
- Roth, S.M., et al., 2002. *IGF2* genotype and obesity in men and women across the adult age span. *Int. J. Obes. Relat. Metab. Disord.* 26, 585–587.
- Shetty, P.J., et al., 2010. Regulation of *IGF2* transcript and protein expression by altered methylation in breast cancer. *J. Cancer Res. Clin. Oncol.* 137, 339–345.
- Steegers-Theunissen, R.P., et al., 2009. Periconceptional maternal folic acid use of 400 microg per day is related to increased methylation of the *IGF2* gene in the very young child. *PLoS One* 4, e7845.
- Stillman, R.J., Rosenberg, M.J., Sachs, B.P., 1986. Smoking and reproduction. *Fertil. Steril.* 46, 545–566.
- Sullivan, M.J., Taniguchi, T., Jhee, A., Kerr, N., Reeve, A.E., 1999. Relaxation of *IGF2* imprinting in Wilms tumours associated with specific changes in *IGF2* methylation. *Oncogene* 18, 7527–7534.
- Takai, D., Gonzales, F.A., Tsai, Y.C., Thayer, M.J., Jones, P.A., 2001. Large scale mapping of methylcytosines in CTCF-binding sites in the human *H19* promoter and aberrant hypomethylation in human bladder cancer. *Hum. Mol. Genet.* 10, 2619–2626.
- Takano, Y., Shiota, G., Kawasaki, H., 2000. Analysis of genomic imprinting of insulin-like growth factor 2 in colorectal cancer. *Oncology* 59, 210–216.
- Taniguchi, T., Sullivan, M.J., Ogawa, O., Reeve, A.E., 1995. Epigenetic changes encompassing the *IGF2/H19* locus associated with relaxation of *IGF2* imprinting and silencing of *H19* in Wilms tumor. *Proc. Natl. Acad. Sci. U. S. A.* 92, 2159–2163.
- Tellez-Plaza, M., Navas-Acien, A., Crainiceanu, C.M., Sharrett, A.R., Guallar, E., 2010. Cadmium and peripheral arterial disease: gender differences in the 1999–2004 US National Health and Nutrition Examination Survey. *Am. J. Epidemiol.* 172, 671–681.
- Tong, V.T., Jones, J.R., Dietz, P.M., D'Angelo, D., Bombard, J.M., 2009. Trends in smoking before, during, and after pregnancy – Pregnancy Risk Assessment Monitoring System (PRAMS), United States, 31 sites, 2000–2005. *MMWR CDC Surveill. Summ.* 58, 1–29.
- Waterland, R.A., et al., 2010. Season of conception in rural gambia affects DNA methylation at putative human metastable epialleles. *PLoS Genet.* 6, e1001252.
- Wong, H.L., et al., 2006. Rapid and quantitative method of allele-specific DNA methylation analysis. *Biotechniques* 41, 734–739.
- Xiao, D., Huang, X., Yang, S., Zhang, L., 2007. Direct effects of nicotine on contractility of the uterine artery in pregnancy. *J. Pharmacol. Exp. Ther.* 322, 180–185.
- Xu, W., Fan, H., He, X., Zhang, J., Xie, W., 2006. LOI of *IGF2* is associated with esophageal cancer and linked to methylation status of *IGF2* DMR. *J. Exp. Clin. Cancer Res.* 25, 543–547.
- Yajnik, C.S., 2004. Early life origins of insulin resistance and type 2 diabetes in India and other Asian countries. *J. Nutr.* 134, 205–210.
- Zuo, Q.S., et al., 2011. Loss of imprinting and abnormal expression of the insulin-like growth factor 2 gene in gastric cancer. *Mol. Carcinog.* 50, 390–396.